WeVote
Log In

Bill

Bill

HB 685

AN ACT relating to the 340B Drug Pricing Program.

2025 Regular Session

HB 685 modifies Kentucky's implementation of the federal 340B drug discount program affecting healthcare provider medication costs and patient access.

to Health Services (H)
#drugsandmedicines #hospitalsandnursinghomes #reportsmandated #stateagencies
0
WeVote Research Nonpartisan
Bill Summary · HB 685

Legislative bill overview

HB 685 relates to modifications of the 340B Drug Pricing Program, a federal program that allows certain healthcare entities (hospitals, clinics, charities) to purchase drugs at significantly discounted prices. The bill's specific provisions are not detailed in the available information, but it addresses how Kentucky will implement or regulate this federal program at the state level.

Why is this important

The 340B program affects drug costs for safety-net hospitals and community health centers, which serve uninsured and low-income patients. Changes to program administration could impact medication affordability for vulnerable populations and the financial sustainability of healthcare providers serving these communities.

Potential points of contention

  • Pharmaceutical industry concerns: Drug manufacturers may oppose expanded 340B protections, as the program reduces their revenue from discounted sales
  • Program integrity vs. access: Debates over oversight mechanisms—stricter auditing could improve accountability but may also create administrative burdens that reduce program participation
  • Definition of eligible entities: Disagreement over which healthcare providers qualify for discounts, potentially affecting competition and program costs

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.